Predictive nomograms of repeat intrahepatic recurrence and overall survival after radiofrequency ablation of recurrent colorectal liver metastases

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–11. doi: 10.3322/caac.21660.
   Web of Science ®Google Scholar
• Sheu MJ, Liang FW, Lin CY, et al. Changes in liver-related mortality by etiology and sequelae: underlying versus multiple causes of death. Popul Health Metr. 2021;19(1):22.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Si XY, Cai ZB, et al. Survival after repeat hepatectomy for recurrent colorectal liver metastasis: a review and meta-analysis of prognostic factors. Hepatobiliary Pancreat Dis Int. 2019;18(4):313–320. doi: 10.1016/j.hbpd.2019.02.003.
   PubMed Web of Science ®Google Scholar
• Wong GYM, Mol B, Bhimani N, et al. Recurrence patterns predict survival after resection of colorectal liver metastases. ANZ J Surg. 2022;92(9):2149–2156. doi: 10.1111/ans.17835.
   PubMed Web of Science ®Google Scholar
• Hof J, Wertenbroek MW, Peeters PM, et al. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg. 2016;103(8):1055–1062. doi: 10.1002/bjs.10162.
   PubMed Web of Science ®Google Scholar
• Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34(1):10–32. doi: 10.1016/j.annonc.2022.10.003.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359. doi: 10.6004/jnccn.2021.0012.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Pedersoli F, Schulze-Hagen M, et al. Salvage RFA in patients with intrahepatic recurrence after major hepatic surgery for colorectal cancer liver metastases: mid-term outcome. Eur Radiol. 2020;30(2):1221–1227. doi: 10.1007/s00330-019-06421-3.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zheng J, Chen H, et al. A prognostic nomogram for colorectal cancer liver metastases after percutaneous thermal ablation. Int J Hyperthermia. 2018;34(6):853–862. doi: 10.1080/02656736.2017.1368095.
   PubMed Web of Science ®Google Scholar
• Qin S, Hu H, Cui R, et al. A prognostic nomogram for intrahepatic progression-free survival in patients with colorectal liver metastases after ultrasound-guided percutaneous microwave ablation. Int J Hyperthermia. 2022;39(1):144–154. doi: 10.1080/02656736.2021.2023226.
   PubMed Web of Science ®Google Scholar
• Wu H, Liu GJ, Zhang ZY, et al. Nomogram including chemotherapy response for prediction of intrahepatic progression-free survival in patients with colorectal liver metastasis through chemotherapy followed by radiofrequency ablation. Int J Hyperthermia. 2021;38(1):633–639. doi: 10.1080/02656736.2021.1912415.
   PubMed Web of Science ®Google Scholar
• Brudvik KW, Jones RP, Giuliante F, et al. RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases. Ann Surg. 2019;269(1):120–126. doi: 10.1097/SLA.0000000000002319.
   PubMed Web of Science ®Google Scholar
• Kitsel Y, Cooke T, Sotirchos V, et al. Colorectal cancer liver metastases: genomics and biomarkers with focus on local therapies. Cancers (Basel). 2023;15(6):1679. doi: 10.3390/cancers15061679.
   PubMed Web of Science ®Google Scholar
• Odisio BC, Yamashita S, Huang SY, et al. Local tumour progression after percutaneous ablation of colorectal liver metastases according to RAS mutation status. Br J Surg. 2017;104(6):760–768. doi: 10.1002/bjs.10490.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Vakiani E, et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget. 2017;8(39):66117–66127. doi: 10.18632/oncotarget.19806.
   PubMedGoogle Scholar
• Puijk RS, Ahmed M, Adam A, et al. Consensus guidelines for the definition of time-to-event end points in image-guided tumor ablation: results of the SIO and DATECAN initiative. Radiology. 2021;301(3):533–540. doi: 10.1148/radiol.2021203715.
   PubMed Web of Science ®Google Scholar
• Ahmed M, Solbiati L, Brace CL, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria–a 10-year update. Radiology. 2014;273(1):241–260. doi: 10.1148/radiol.14132958.
   PubMed Web of Science ®Google Scholar
• Wang X, Sofocleous CT, Erinjeri JP, et al. Margin size is an independent predictor of local tumor progression after ablation of Colon cancer liver metastases. Cardiovasc Intervent Radiol. 2013;36(1):166–175. doi: 10.1007/s00270-012-0377-1.
   PubMed Web of Science ®Google Scholar
• Yan XL, Wang K, Bao Q, et al. Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy. J Surg Oncol. 2022;125(6):1002–1012. doi: 10.1002/jso.26816.
   PubMed Web of Science ®Google Scholar
• Liu W, Liu JM, Wang K, et al. Recurrent colorectal liver metastasis patients could benefit from repeat hepatic resection. BMC Surg. 2021;21(1):327. doi: 10.1186/s12893-021-01323-y.
   PubMed Web of Science ®Google Scholar
• Valls C, Ramos E, Leiva D, et al. Safety and efficacy of ultrasound-guided radiofrequency ablation of recurrent colorectal cancer liver metastases after hepatectomy. Scand J Surg. 2015;104(3):169–175. doi: 10.1177/1457496914553147.
   PubMed Web of Science ®Google Scholar
• Dijkstra M, Nieuwenhuizen S, Puijk RS, et al. Thermal ablation compared to partial hepatectomy for recurrent colorectal liver metastases: an Amsterdam colorectal liver met registry (AmCORE) based study. Cancers (Basel). 2021;13(11):2769. doi: 10.3390/cancers13112769.
   Web of Science ®Google Scholar
• Chun YS, Passot G, Yamashita S, et al. Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases. Ann Surg. 2019;269(5):917–923. doi: 10.1097/SLA.0000000000002450.
   PubMed Web of Science ®Google Scholar
• Zimmitti G, Shindoh J, Mise Y, et al. RAS mutations predict radiologic and pathologic response in patients treated with chemotherapy before resection of colorectal liver metastases. Ann Surg Oncol. 2015;22(3):834–842. doi: 10.1245/s10434-014-4042-6.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Peng J, Ye M, et al. KRAS mutation predicted more mirometastases and closer resection margins in patients with colorectal cancer liver metastases. Ann Surg Oncol. 2020;27(4):1164–1173. doi: 10.1245/s10434-019-08065-5.
   PubMed Web of Science ®Google Scholar
• Calandri M, Yamashita S, Gazzera C, et al. Ablation of colorectal liver metastasis: interaction of ablation margins and RAS mutation profiling on local tumour progression-free survival. Eur Radiol. 2018;28(7):2727–2734. doi: 10.1007/s00330-017-5273-2.
   PubMed Web of Science ®Google Scholar
• Jiang BB, Yan K, Zhang ZY, et al. The value of KRAS gene status in predicting local tumor progression of colorectal liver metastases following radiofrequency ablation. Int J Hyperthermia. 2019;36(1):211–219.
   PubMed Web of Science ®Google Scholar
• Shady W, Petre EN, Do KG, et al. Percutaneous microwave versus radiofrequency ablation of colorectal liver metastases: ablation with clear margins (A0) provides the best local tumor control. J Vasc Interv Radiol. 2018;29(2):268–275.e261. doi: 10.1016/j.jvir.2017.08.021.
   PubMed Web of Science ®Google Scholar
• Han K, Kim JH, Yang SG, et al. A single-center retrospective analysis of periprocedural variables affecting local tumor progression after radiofrequency ablation of colorectal cancer liver metastases. Radiology. 2021;298(1):212–218. doi: 10.1148/radiol.2020200109.
   PubMed Web of Science ®Google Scholar
• Chlorogiannis DD, Sotirchos VS, Georgiades C, et al. The importance of optimal thermal ablation margins in colorectal liver metastases: a systematic review and meta-analysis of 21 studies. Cancers (Basel). 2023;15(24):5806. doi: 10.3390/cancers15245806.
   PubMed Web of Science ®Google Scholar
• Laimer G, Jaschke N, Schullian P, et al. Volumetric assessment of the periablational safety margin after thermal ablation of colorectal liver metastases. Eur Radiol. 2021;31(9):6489–6499. doi: 10.1007/s00330-020-07579-x.
   PubMed Web of Science ®Google Scholar
• Vasiniotis Kamarinos N, Gonen M, Sotirchos V, et al. 3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases. Int J Hyperthermia. 2022;39(1):880–887. doi: 10.1080/02656736.2022.2055795.
   PubMed Web of Science ®Google Scholar
• Lin YM, Paolucci I, O’Connor CS, et al. Ablative margins of colorectal liver metastases using deformable CT image registration and autosegmentation. Radiology. 2023;307(2):e221373. doi: 10.1148/radiol.221373.
   PubMed Web of Science ®Google Scholar
• Zirakchian Zadeh M, Yeh R, Kunin HS, et al. Real-time split-dose PET/CT-guided ablation improves colorectal liver metastasis detection and ablation zone margin assessments without the need for repeated contrast injection. Cancers (Basel). 2022;14(24):6253. doi: 10.3390/cancers14246253.
   PubMed Web of Science ®Google Scholar
• Zirakchian Zadeh M, Yeh R, Kirov AS, et al. Gradient-based volumetric PET parameters on immediate pre-ablation FDG-PET predict local tumor progression in patients with colorectal liver metastasis treated by microwave ablation. Cardiovasc Intervent Radiol. 2023;46(7):911–920. doi: 10.1007/s00270-023-03470-6.
   PubMed Web of Science ®Google Scholar
• Cornelis FH, Petre EN, Vakiani E, et al. Immediate postablation (18)F-FDG injection and corresponding SUV are surrogate biomarkers of local tumor progression after thermal ablation of colorectal carcinoma liver metastases. J Nucl Med. 2018;59(9):1360–1365. doi: 10.2967/jnumed.117.194506.
   PubMed Web of Science ®Google Scholar
• Zirakchian Zadeh M, Sotirchos VS, Kirov A, et al. Three-dimensional margin as a predictor of local tumor progression after microwave ablation: intraprocedural versus 4-8-week postablation assessment. J Vasc Interv Radiol. 2024;10:S1051-0443(24)00004-6.
   Google Scholar
• Vasiniotis Kamarinos N, Vakiani E, Gonen M, et al. Biopsy and margins optimize outcomes after thermal ablation of colorectal liver metastases. Cancers (Basel). 2022;14(3):693. doi: 10.3390/cancers14030693.
   PubMed Web of Science ®Google Scholar
• Vasiniotis Kamarinos N, Vakiani E, Fujisawa S, et al. Immunofluorescence assay of ablated colorectal liver metastases: the frozen section of image-guided tumor ablation? J Vasc Interv Radiol. 2022;33(3):308–315.e301. doi: 10.1016/j.jvir.2021.11.008.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Mauer M, Gruenberger T, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC intergroup trial 40983). Ann Surg. 2012;255(3):534–539. doi: 10.1097/SLA.0b013e3182456aa2.
   PubMed Web of Science ®Google Scholar
• Battula N, Tsapralis D, Mayer D, et al. Repeat liver resection for recurrent colorectal metastases: a single-centre, 13-year experience. HPB (Oxford). 2014;16(2):157–163. doi: 10.1111/hpb.12096.
   PubMed Web of Science ®Google Scholar
• Sofocleous CT, Petre EN, Gonen M, et al. CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy. J Vasc Interv Radiol. 2011;22(6):755–761. doi: 10.1016/j.jvir.2011.01.451.
   PubMed Web of Science ®Google Scholar
• Gillams A, Goldberg N, Ahmed M, et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, the interventional oncology sans frontières meeting 2013. Eur Radiol. 2015;25(12):3438–3454. doi: 10.1007/s00330-015-3779-z.
   PubMed Web of Science ®Google Scholar
• Dijkstra M, Nieuwenhuizen S, Puijk RS, et al. Repeat local treatment of recurrent colorectal liver metastases, the role of neoadjuvant chemotherapy: an Amsterdam colorectal liver met registry (AmCORE) based study. Cancers (Basel). 2021;13(19):4997. doi: 10.3390/cancers13194997.
   Web of Science ®Google Scholar